| Kristen Gerjevic, MD | |
|
7710 Mercy Rd Ste 1000, Omaha, NE 68124-2323 | |
| (402) 717-3010 | |
| (402) 391-0298 |
| Full Name | Kristen Gerjevic |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 11 Years |
| Location | 7710 Mercy Rd Ste 1000, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780927301 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi Health Bergan Mercy | Omaha, NE | Hospital |
| Chi Health Lakeside | Omaha, NE | Hospital |
| Chi Health Mercy Council Bluffs | Council bluffs, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alegent Creighton Clinic | 1951210418 | 827 |
News Archive
Researchers from Mount Sinai School of Medicine have found that hospitalized patients with dysphagia, or difficulty swallowing, averaged a 40 percent longer hospital stay than patients without the condition. They also had a generally poorer prognosis. The research is published in the August issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.
For parents around the world, premixed infant cereals-also known as complementary foods-can be a vital source of the solid food needed for healthy child growth after six months of age, when infants outgrow the nutrients provided by breast milk alone.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
The Neonatal Intensive Care Unit (NICU) at Children's Medical Center has been designated a Level IV NICU, the highest qualification for such programs, as established by the American Academy of Pediatrics under newly revised standards.
Angiotech Pharmaceuticals, Inc. today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, has enrolled the first patient in its landmark Formula PTX clinical trial. The trial is the first of its kind to evaluate the safety and effectiveness of a paclitaxel-eluting stent to treat renal artery disease, the narrowing of the arteries that supply blood to the kidneys.
› Verified 5 days ago
| Entity Name | Alegent Creighton Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548287907 PECOS PAC ID: 1951210418 Enrollment ID: O20040407001314 |
News Archive
Researchers from Mount Sinai School of Medicine have found that hospitalized patients with dysphagia, or difficulty swallowing, averaged a 40 percent longer hospital stay than patients without the condition. They also had a generally poorer prognosis. The research is published in the August issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.
For parents around the world, premixed infant cereals-also known as complementary foods-can be a vital source of the solid food needed for healthy child growth after six months of age, when infants outgrow the nutrients provided by breast milk alone.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
The Neonatal Intensive Care Unit (NICU) at Children's Medical Center has been designated a Level IV NICU, the highest qualification for such programs, as established by the American Academy of Pediatrics under newly revised standards.
Angiotech Pharmaceuticals, Inc. today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, has enrolled the first patient in its landmark Formula PTX clinical trial. The trial is the first of its kind to evaluate the safety and effectiveness of a paclitaxel-eluting stent to treat renal artery disease, the narrowing of the arteries that supply blood to the kidneys.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Gerjevic, MD 7261 Mercy Rd, Omaha, NE 68124-2311 Ph: () - | Kristen Gerjevic, MD 7710 Mercy Rd Ste 1000, Omaha, NE 68124-2323 Ph: (402) 717-3010 |
News Archive
Researchers from Mount Sinai School of Medicine have found that hospitalized patients with dysphagia, or difficulty swallowing, averaged a 40 percent longer hospital stay than patients without the condition. They also had a generally poorer prognosis. The research is published in the August issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.
For parents around the world, premixed infant cereals-also known as complementary foods-can be a vital source of the solid food needed for healthy child growth after six months of age, when infants outgrow the nutrients provided by breast milk alone.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
The Neonatal Intensive Care Unit (NICU) at Children's Medical Center has been designated a Level IV NICU, the highest qualification for such programs, as established by the American Academy of Pediatrics under newly revised standards.
Angiotech Pharmaceuticals, Inc. today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, has enrolled the first patient in its landmark Formula PTX clinical trial. The trial is the first of its kind to evaluate the safety and effectiveness of a paclitaxel-eluting stent to treat renal artery disease, the narrowing of the arteries that supply blood to the kidneys.
› Verified 5 days ago
Dr. Elizabeth Stephens Constance, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 7308 S 142nd St, Omaha, NE 68138 Phone: 402-717-4200 | |
Jennifer Marie Burgart, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 7710 Mercy Rd Ste 202, Omaha, NE 68124 Phone: 402-280-4438 | |
Dr. Grace Binter, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 983255 Nebraska Medical Ctr, Omaha, NE 68198 Phone: 402-559-6160 | |
Dr. Stephanie Lynn Fisher Gustin, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 7308 S 142nd St, Omaha, NE 68138 Phone: 402-717-4200 Fax: 402-717-4231 | |
Dr. Alex Keith Laudenklos, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 601 N 30th St, Cu Department Of Obstetrics And Gynecology, Omaha, NE 68131 Phone: 402-717-0947 | |
Mr. Kent Harry Siemers, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 7205 W Center Rd, Suite 200, Omaha, NE 68124 Phone: 402-397-6600 Fax: 402-397-8318 | |
Dr. Brent Jonathan Tierney, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 8303 Dodge St, Suite 300, Omaha, NE 68114 Phone: 402-354-5250 Fax: 402-354-3437 |